### No oxygen support (early COVID-19, but at high risk of progression)

#### Recommended
- Neutralising monoclonal antibodies
  - (See policy for more details)
  - Aged 12 or over, and weight 40 kg or over, and
  - who are not in hospital

#### Conditional for
- Nirmatrelvir and ritonavir
  - (See policy for more details)
  - Aged 18 or over, and
  - within 5 days of symptom onset

- Remdesivir
  - (See policy for more details)
  - Aged 12 or over, and weight 40 kg or over, and
  - within 7 days of symptom onset

- Molnupiravir
  - (See policy for more details)
  - Aged 18 or over, and
  - within 5 days of symptom onset

### Low-flow oxygen (COVID-19 pneumonia)

#### Recommended
- Corticosteroids (dexamethasone, or either hydrocortisone or prednisolone)

#### Conditional for
- Tocilizumab
  - (See policy for more details)
  - If C-reactive protein is 75 mg/litre or more

- Sarilumab
  - (See policy for more details)
  - If tocilizumab unavailable or cannot be used, and
  - C-reactive protein level is 75 mg/litre or more

- Baricitinib
  - Adults

### High-flow oxygen/CPAP/mechanical ventilation (COVID-19 pneumonia)

#### Recommended
- Tocilizumab
  - (See policy for more details)
  - If within 48 hours of starting this level of support

#### Conditional for
- Sarilumab
  - (See policy for more details)
  - If tocilizumab unavailable or cannot be used, and
  - within 48 hours of starting this level of support (see policy)

- Baricitinib
  - Adults

- Remdesivir
  - Aged 12 or over and weight 40 kg or over

- Low molecular weight heparin (treatment dose)
  - Adults or young people, if no increased bleeding risk

- Casirivimab and imdevimab
  - If no detectable SARS-CoV-2 antibodies (seronegative), and aged 12 or over, and
  - infection known to be caused by variant susceptible to casirivimab and imdevimab
Managing COVID 19: treatments (July 2022 v27.0)

- **High-flow oxygen/CPAP/mechanical ventilation (COVID-19 pneumonia)**
  - **Tocilizumab**
    - For children and young people aged 1 year or over who have severe COVID-19 or paediatric inflammatory multisystem syndrome
  - **Remdesivir**
    - Low molecular weight heparin (intermediate or treatment dose)
    - For adults or young people, if no increased bleeding risk
  - **Ivermectin**
  - **Vitamin D**
  - **Casirivimab and imdevimab**
    - If infection known to be caused by omicron variant, or any other variant not susceptible to casirivimab and imdevimab
  - **Molnupiravir**
    - For children and young people aged under 18, or pregnant women
  - **Azithromycin**
  - **Colchicine**
  - **Doxycycline**
  - **Corticosteroids**

- **Low-flow oxygen (COVID-19 pneumonia)**
  - **Budesonide (inhaled)**

- **No oxygen support (early COVID-19, but at high risk of progression)**
  - **Only in research**
    - The option should only be available as part of a clinical trial.
  - **Not recommended**
    - All or nearly all informed people would likely decline this option.

This is a summary of the advice in the NICE guideline COVID-19 rapid guideline: managing COVID-19.

© NICE 2022. All rights reserved. Subject to Notice of rights.